Cheng-Yang Chou
Overview
Explore the profile of Cheng-Yang Chou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu Y, Huang Y, Wu P, Chang T, Huang S, Chou C
J Ovarian Res
. 2023 Jun;
16(1):124.
PMID: 37386587
Background: MicroRNAs are a group of small non-coding RNAs that are involved in development and diseases such as cancer. Previously, we demonstrated that miR-335 is crucial for preventing collagen type...
2.
Wu Y, Huang Y, Wu P, Chang T, Huang S, Chou C
Res Sq
. 2023 Mar;
PMID: 36865240
Background MicroRNAs are a group of small non-coding RNAs that are involved in development and diseases such as cancer. Previously, we demonstrated that miR-335 is crucial for preventing collagen type...
3.
Wu Y, Chou C
Front Oncol
. 2022 Jul;
12:925165.
PMID: 35847935
The extracellular matrix (ECM) plays an important role in the progression of cancer. Collagen is the most abundant component in ECM, and is involved in the biological formation of cancer....
4.
Chou C, Cheng W, Chen M, Lin H, Ho C, Hung Y, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406519
This large-scale study aimed to determine the long-term influences of potential prognostic predictors and progression-free interval (PFI) criteria for grading platinum-sensitivity in ovarian clear cell carcinoma (OCCC). We retrospectively reviewed...
5.
Wu Y, Huang Y, Chang T, Wu P, Hsieh T, Hsiao S, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944877
High collagen type XI alpha 1 (COL11A1) levels are associated with tumor progression, chemoresistance, and poor patient survival in several cancer types. MicroRNAs (miRNAs) are dysregulated in multiple cancers, including...
6.
Kuo M, Huang Y, Chou C, Chen H
Pharmaceuticals (Basel)
. 2021 Jul;
14(6).
PMID: 34201235
The platinum (Pt)-containing antitumor drugs including cisplatin (cis-diamminedichloroplatinum II, cDDP), carboplatin, and oxaliplatin, have been the mainstay of cancer chemotherapy. These drugs are effective in treating many human malignancies. The...
7.
Wu Y, Huang Y, Chang T, Chen C, Wu P, Huang S, et al.
Oncogene
. 2021 Jun;
40(26):4503-4519.
PMID: 34117361
Ovarian cancer has a unique tumor microenvironment (TME) that enables cancer-associated fibroblasts (CAFs) to interact with cellular and matrix constituents and influence tumor development and migration into the peritoneal cavity....
8.
Wu P, Cheng Y, Shen M, Chen Y, Huang Y, Chou C
Front Oncol
. 2020 Aug;
10:1095.
PMID: 32760668
This study aimed to determine the real-world, long-term prognostic impacts, and adverse effects (AEs) of bevacizumab (BEV) in Asian patients with ovarian/tubal/peritoneal cancers. We retrospectively reviewed the medical records of...
9.
Wu Y, Huang Y, Chen C, Huang C, Chou C
Front Pharmacol
. 2020 Mar;
11:206.
PMID: 32194423
Epithelial ovarian carcinoma (EOC) is the most lethal gynecological malignancy. Herein, we sought to determine the efficacy of phosphoinositide 3-kinase (PI3K)/Akt inhibition using three AZD compounds in a NOD-SCID xenograft...
10.
Huang H, Lin Y, Chang H, Lai Y, Chen Y, Huang S, et al.
J Biomed Sci
. 2020 Feb;
27(1):36.
PMID: 32079527
Background: Among gynecological cancers, ovarian carcinoma has the highest mortality rate, and chemoresistance is highly prevalent in this cancer. Therefore, novel strategies are required to improve its poor prognosis. Formation...